Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

The tumor sample reports that you printed are where oncology is headed, as a variety of articles referenced on the board recently have suggested- the one in the NYT about treatment based on genetics, and not based on organ of origin of a tumor, and the other referencing a Cell(I think) article about sorting out possible treatment alternatives in 16 hours(yowza).

Look: the reason for all of the focus on p53 is because if you had the same report on every person with cancer in the US about half would mention p53 as a genetic mutation and therefore a potential target. It is nice to see that they reference Kevetrin as a potential treatment.

Now we just have to wait patiently to see if the mouse data translate into human success